投资机构Canaccord Genuity近日发布最新研报,将拜玛林制药(Biomarin Pharmaceutical)的投资评级从"持有"显著上调至"买入"级别。与此同时,该机构将其目标股价从原先的84美元大幅调升至98美元,显示出对该公司未来发展的强烈信心。
此次评级调整反映了分析师对拜玛林制药核心业务增长前景的乐观预期。目标价的大幅提升也预示着该机构认为公司股价具备可观的上涨空间。
投资机构Canaccord Genuity近日发布最新研报,将拜玛林制药(Biomarin Pharmaceutical)的投资评级从"持有"显著上调至"买入"级别。与此同时,该机构将其目标股价从原先的84美元大幅调升至98美元,显示出对该公司未来发展的强烈信心。
此次评级调整反映了分析师对拜玛林制药核心业务增长前景的乐观预期。目标价的大幅提升也预示着该机构认为公司股价具备可观的上涨空间。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.